Reed Mirembe, Kerndt Connor C., Nicolas Diala
Spectrum Health/Michigan State University College of Human Medicine
Steward St. Elizabeth's Medical Center
Alteplase is a thrombolytic agent that is manufactured by recombinant DNA technology. It is FDA approved for use in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters. Off-label indications include catheter-directed thrombolysis in the treatment of peripheral arterial occlusive disease and deep vein thrombosis. This activity outlines the indications, contraindications, activity, adverse events, and toxicity of alteplase in the clinical setting as relates to the essential points necessary for members of an interprofessional team managing the care of patients in need of thrombolytic therapy.
阿替普酶是一种通过重组DNA技术制造的溶栓剂。它已获得美国食品药品监督管理局（FDA）批准，用于治疗急性缺血性中风、肺栓塞、急性心肌梗死和导管阻塞。其非标签适应症包括用于治疗外周动脉闭塞性疾病和深静脉血栓形成的导管定向溶栓。本活动概述了阿替普酶在临床环境中的适应症、禁忌症、作用、不良事件和毒性，这些与跨专业团队成员管理需要溶栓治疗的患者护理所需的要点相关。
